Neurotensinergic neurons are specialized neurons that produce and release neurotensin (NT), a 13-amino acid neuropeptide originally isolated from the bovine hypothalamus in 1973. This neuropeptide acts as both a neuropeptide (released from dense core vesicles) and a neuromodulator (modulating GABAergic and dopaminergic transmission), playing crucial roles in pain modulation, dopamine signaling, neuroprotection, and various neuropsychiatric processes. Neurotensinergic neurons are distributed throughout the central nervous system, with particularly high concentrations in the hypothalamus, substantia nigra, ventral tegmental area, and central gray matter[@tylermcmahon2000][@stalla2010].
Neurotensin interacts with two G protein-coupled receptors: NTS1 (high-affinity, signal transduction through Gq/11) and NTS2 (lower-affinity, signaling through Gi/o). A third receptor, NTS3 (also called sortilin), functions as a neurotensin clearance receptor. The distribution of these receptors in the brain closely matches the locations of neurotensinergic neurons, enabling precise paracrine and autocrine signaling.
Neurotensin: The Signaling Molecule
Peptide Structure and Processing
Neurotensin is synthesized as a larger precursor (pre-neurotensin/neuromedin N precursor) and processed into multiple forms:
...
Neurotensinergic Neurons
Overview
Neurotensinergic neurons are specialized neurons that produce and release neurotensin (NT), a 13-amino acid neuropeptide originally isolated from the bovine hypothalamus in 1973. This neuropeptide acts as both a neuropeptide (released from dense core vesicles) and a neuromodulator (modulating GABAergic and dopaminergic transmission), playing crucial roles in pain modulation, dopamine signaling, neuroprotection, and various neuropsychiatric processes. Neurotensinergic neurons are distributed throughout the central nervous system, with particularly high concentrations in the hypothalamus, substantia nigra, ventral tegmental area, and central gray matter[@tylermcmahon2000][@stalla2010].
Neurotensin interacts with two G protein-coupled receptors: NTS1 (high-affinity, signal transduction through Gq/11) and NTS2 (lower-affinity, signaling through Gi/o). A third receptor, NTS3 (also called sortilin), functions as a neurotensin clearance receptor. The distribution of these receptors in the brain closely matches the locations of neurotensinergic neurons, enabling precise paracrine and autocrine signaling.
Neurotensin: The Signaling Molecule
Peptide Structure and Processing
Neurotensin is synthesized as a larger precursor (pre-neurotensin/neuromedin N precursor) and processed into multiple forms:
| Form | Length | Function | |------|--------|----------| | Neurotensin (NT) | 13 aa | Primary active form | | Neurotensin(1-8) | 8 aa | N-terminal fragment, active | | Neuromedin N | 13 aa | Related peptide, same precursor |
Receptor Signaling
NTS1 Receptor (High Affinity)
Affinity: KD ~ 0.1 nM
G Protein: Gq/11 → PLC → IP3/DAG → Ca2+ mobilization
Signaling: PKC activation, MAPK pathways
Desensitization: GRK-mediated phosphorylation
NTS2 Receptor (Low Affinity)
Affinity: KD ~ 5-10 nM
G Protein: Gi/o → inhibition of adenylate cyclase
Signaling: Modulation of neuronal excitability
Distribution: Broader than NTS1
NTS3/Sortilin
Function: Clearance and transport
Role: Modulates NT availability
Pathology: Implicated in neurodegenerative diseases
Anatomical Distribution
Brain Regions with Neurotensinergic Neurons
| Region | Density | Function | |--------|---------|-----------| | Hypothalamus (periventricular, arcuate) | High | Neuroendocrine regulation | | Substantia Nigra (pars compacta) | High | Modulation of dopamine neurons | | Ventral Tegmental Area | High | Reward and motivation | | Central Gray Matter | Moderate | Pain modulation | | Bed Nucleus of Stria Terminalis | Moderate | Stress response | | Amygdala | Moderate | Emotional processing | | Prefrontal Cortex | Low | Cognitive modulation |
Projection Patterns
Neurotensinergic neurons project to:
Substantia Pars Compacta → Modulates dopaminergic neuron firing
Ventral Tegmental Area → Influences mesolimbic dopamine pathways
Striatum → Direct modulation of motor control circuits
[Tyler-McMahon BM, Boules M, Richelson E, Neurotensin: role as a modulator of dopaminergic transmission (2000)](https://doi.org/10.1007/978-3-0348-8401-5_5)
[Stalla GK, Loidl P, Uhl E, et al, Neurotensin in the central nervous system: biological actions and therapeutic potential (2010)](https://doi.org/10.1007/s00441-010-1014-5)
[Katsurd N, Bhardwaj S, Huang W, et al, Neurotensin and dopamine interactions in neuropsychiatric diseases (2018)](https://doi.org/10.1002/jnr.24112)
[Liu Y, Cheng J, Ouyang Q, et al, Neurotensin and neuroprotection in Parkinson's disease (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.015)
[Dubois M, Emond S, Bernard V, et al, Neurotensin and pain modulation (2021)](https://doi.org/10.1097/01.pain.0000569768.98765.4a)
[Toth K, Loven T, Nuss J, et al, Neurotensin in schizophrenia and bipolar disorder (2013)](https://doi.org/10.1016/j.pnpbp.2013.01.003)
[Caceda R, Kinkead B, Nemeroff CB, Neurotensin: role in psychiatric and neurological diseases (2006)](https://doi.org/10.1016/j.peptides.2006.05.012)
[Muller TD, Culler M, Esser J, et al, Neurotensin receptor agonists for obesity treatment (2019)](https://doi.org/10.1038/s41573-019-0012-7)
[Kumar R, Tripathi M, Ahmad M, et al, CSF neurotensin as biomarker in neurodegenerative diseases (2017)](https://doi.org/10.1007/s00415-017-8442-4)
[Richardson PJ, Kase H, Jenner PG, Antipsychotic drug development: the role of neurotensin (2010)](https://doi.org/10.1016/j.tips.2010.02.005)